Oxolife — Series A · €5M

Oxolife is a biotech working on female fertility. It raised €5M in its first round, which El Referente calls a Series A, to fund a Phase II trial of OXO-001, a molecule meant to improve embryo implantation in assisted reproduction. Inveready led through Inveready Biotech III, with CDTI (Innvierte) co-investing and about €1.2M coming from private investors through Capital Cell.